Symbols / WVE
WVE Chart
About
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.44B |
| Enterprise Value | 1.94B | Income | -121.95M | Sales | 109.23M |
| Book/sh | 0.78 | Cash/sh | 1.17 | Dividend Yield | — |
| Payout | 0.00% | Employees | 287 | IPO | — |
| P/E | — | Forward P/E | -10.60 | PEG | — |
| P/S | 22.31 | P/B | 16.89 | P/C | — |
| EV/EBITDA | -14.62 | EV/Sales | 17.73 | Quick Ratio | 2.40 |
| Current Ratio | 2.51 | Debt/Eq | 14.93 | LT Debt/Eq | — |
| EPS (ttm) | -0.65 | EPS next Y | -1.24 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-03 | ROA | -28.33% |
| ROE | -86.51% | ROIC | — | Gross Margin | -59.86% |
| Oper. Margin | -7.41% | Profit Margin | -111.64% | Shs Outstand | 185.76M |
| Shs Float | 84.16M | Short Float | 10.52% | Short Ratio | 3.42 |
| Short Interest | — | 52W High | 21.73 | 52W Low | 5.28 |
| Beta | -1.77 | Avg Volume | 6.92M | Volume | 1.33M |
| Target Price | $33.38 | Recom | Strong_buy | Prev Close | $12.59 |
| Price | $13.12 | Change | 4.21% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$33.38
Mean price target
2. Current target
$13.13
Latest analyst target
3. DCF / Fair value
$-14.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.13
Low
$22.00
High
$50.00
Mean
$33.38
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-12 | main | Wells Fargo | Overweight → Overweight | $27 |
| 2026-02-05 | main | Cantor Fitzgerald | Overweight → Overweight | $41 |
| 2026-02-03 | main | Canaccord Genuity | Buy → Buy | $43 |
| 2025-12-19 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-12-16 | main | Oppenheimer | Outperform → Outperform | $32 |
| 2025-12-15 | main | Truist Securities | Buy → Buy | $50 |
| 2025-12-12 | main | B. Riley Securities | Buy → Buy | $37 |
| 2025-12-12 | main | Wedbush | Outperform → Outperform | $33 |
| 2025-12-09 | main | Citigroup | Buy → Buy | $30 |
| 2025-12-09 | main | Canaccord Genuity | Buy → Buy | $40 |
| 2025-12-09 | main | Wells Fargo | Overweight → Overweight | $29 |
| 2025-12-09 | main | Cantor Fitzgerald | Overweight → Overweight | $34 |
| 2025-12-09 | main | Clear Street | Buy → Buy | $47 |
| 2025-12-09 | up | RBC Capital | Sector Perform → Outperform | $27 |
| 2025-11-11 | main | Wedbush | Outperform → Outperform | $20 |
| 2025-11-11 | main | Wells Fargo | Overweight → Overweight | $16 |
| 2025-10-15 | init | Clear Street | — → Buy | $22 |
| 2025-09-04 | main | Wells Fargo | Overweight → Overweight | $18 |
| 2025-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-08-04 | init | Canaccord Genuity | — → Buy | $19 |
News
RSS: Latest WVE news- BofA Highlights WVE-007 as Primary Driver For Wave Life Sciences Ltd. (WVE)'s Growth, Projecting Peak Sales Above $11B - Finviz Wed, 18 Feb 2026 07
- Wave Life Sciences: WVE-006 Now In Focus, Navigating Opportunity And Risk (NASDAQ:WVE) - Seeking Alpha ue, 17 Feb 2026 14
- (WVE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily Wed, 18 Feb 2026 11
- Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program - Yahoo Finance Mon, 16 Feb 2026 17
- BofA Highlights WVE-007 as Primary Driver For Wave Life Sciences Ltd. (WVE)’s Growth, Projecting Peak Sales Above $11B - Insider Monkey Wed, 18 Feb 2026 07
- WVE Stock Update: Wells Fargo Adjusts Price Target Amidst Steady - GuruFocus hu, 12 Feb 2026 15
- WAVE Life Sciences (NASDAQ:WVE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat hu, 05 Feb 2026 08
- $WVE stock is up 26% today. Here's what we see in our data. - Quiver Quantitative ue, 06 Jan 2026 08
- Wave RNA drug for rare lung and liver disease heads for FDA talks - Stock Titan Mon, 02 Feb 2026 08
- Why Wave Life Sciences Stock Crushed it Again Today - Nasdaq ue, 09 Dec 2025 08
- Why Wave Life Sciences Stock Crushed it Again Today - The Motley Fool ue, 09 Dec 2025 08
- WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally? - Yahoo Finance hu, 11 Dec 2025 08
- WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat Mon, 16 Feb 2026 06
- Insider Purchase: 10% owner at $WVE Buys 1,470,000 Shares | WVE Stock News - Quiver Quantitative Mon, 15 Dec 2025 08
- Wave Life Sciences (Nasdaq: WVE) begins $250M share and pre-funded warrant sale - Stock Titan Mon, 08 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3588 | 48259 | — | Sale at price 13.45 per share. | MORAN KYLE | Chief Financial Officer | — | 2026-02-09 00:00:00 | D |
| 1 | 10480 | 140956 | — | Sale at price 13.45 per share. | BOLNO PAUL B. M.D. | Chief Executive Officer | — | 2026-02-09 00:00:00 | D |
| 2 | 3228 | 43417 | — | Sale at price 13.45 per share. | VARGEESE CHANDRA | Officer | — | 2026-02-09 00:00:00 | D |
| 3 | 1883 | 25326 | — | Sale at price 13.45 per share. | FRANCIS CHRISTOPHER JOHN | Officer | — | 2026-02-09 00:00:00 | D |
| 4 | 45625 | — | — | Stock Award(Grant) at price 0.00 per share. | MORAN KYLE | Chief Financial Officer | — | 2026-02-05 00:00:00 | D |
| 5 | 165000 | — | — | Stock Award(Grant) at price 0.00 per share. | BOLNO PAUL B. M.D. | Chief Executive Officer | — | 2026-02-05 00:00:00 | D |
| 6 | 45625 | — | — | Stock Award(Grant) at price 0.00 per share. | VARGEESE CHANDRA | Officer | — | 2026-02-05 00:00:00 | D |
| 7 | 38750 | — | — | Stock Award(Grant) at price 0.00 per share. | FRANCIS CHRISTOPHER JOHN | Officer | — | 2026-02-05 00:00:00 | D |
| 8 | 9375 | 150260 | — | Sale at price 15.92 - 16.70 per share. | FRANCIS CHRISTOPHER JOHN | Officer | — | 2026-01-02 00:00:00 | D |
| 9 | 9375 | 29438 | — | Conversion of Exercise of derivative security at price 3.14 per share. | FRANCIS CHRISTOPHER JOHN | Officer | — | 2026-01-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 95.14K | 267.07K | 60.00 |
| TaxRateForCalcs | 0.00 | 0.01 | 0.17 | 0.00 |
| NormalizedEBITDA | -111.90M | -66.72M | -154.18M | -117.21M |
| TotalUnusualItems | 10.16M | 7.93M | 1.57M | 30.00K |
| TotalUnusualItemsExcludingGoodwill | 10.16M | 7.93M | 1.57M | 30.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -97.01M | -57.51M | -161.82M | -122.25M |
| ReconciledDepreciation | 8.66M | 9.21M | 10.11M | 9.84M |
| EBITDA | -101.74M | -58.79M | -152.61M | -117.18M |
| EBIT | -110.40M | -68.00M | -162.72M | -127.02M |
| NormalizedIncome | -107.17M | -65.35M | -163.13M | -122.27M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -97.01M | -57.51M | -161.82M | -122.25M |
| TotalExpenses | 218.71M | 181.30M | 166.37M | 167.98M |
| TotalOperatingIncomeAsReported | -110.40M | -68.00M | -162.72M | -127.02M |
| DilutedAverageShares | 138.28M | 106.10M | 78.86M | 51.83M |
| BasicAverageShares | 138.28M | 106.10M | 78.86M | 51.83M |
| DilutedEPS | -0.70 | -0.54 | -2.05 | -2.36 |
| BasicEPS | -0.70 | -0.54 | -2.05 | -2.36 |
| DilutedNIAvailtoComStockholders | -97.01M | -57.51M | -161.82M | -122.25M |
| NetIncomeCommonStockholders | -97.01M | -57.51M | -161.82M | -122.25M |
| NetIncome | -97.01M | -57.51M | -161.82M | -122.25M |
| NetIncomeIncludingNoncontrollingInterests | -97.01M | -57.51M | -161.82M | -122.25M |
| NetIncomeContinuousOperations | -97.01M | -57.51M | -161.82M | -122.25M |
| TaxProvision | 0.00 | -677.00K | 681.00K | -204.00K |
| PretaxIncome | -97.01M | -58.19M | -161.14M | -122.45M |
| OtherIncomeExpense | 13.39M | 9.81M | 1.58M | 4.57M |
| OtherNonOperatingIncomeExpenses | 3.23M | 1.88M | 7.00K | 4.54M |
| GainOnSaleOfSecurity | 10.16M | 7.93M | 1.57M | 30.00K |
| OperatingIncome | -110.40M | -68.00M | -162.72M | -127.02M |
| OperatingExpense | 218.71M | 181.30M | 166.37M | 167.98M |
| ResearchAndDevelopment | 159.68M | 130.01M | 115.86M | 121.88M |
| SellingGeneralAndAdministration | 59.02M | 51.29M | 50.51M | 46.10M |
| GeneralAndAdministrativeExpense | 59.02M | 51.29M | 50.51M | 46.10M |
| OtherGandA | 59.02M | 51.29M | 50.51M | 46.10M |
| TotalRevenue | 108.30M | 113.31M | 3.65M | 40.96M |
| OperatingRevenue | 108.30M | 113.31M | 3.65M | 40.96M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 153.04M | 119.16M | 86.92M | 59.84M |
| ShareIssued | 153.04M | 119.16M | 86.92M | 59.84M |
| TotalDebt | 25.40M | 32.12M | 37.61M | 29.92M |
| TangibleBookValue | 209.51M | 39.63M | -45.09M | 32.50M |
| InvestedCapital | 209.51M | 39.63M | -45.09M | 32.50M |
| WorkingCapital | 209.44M | 48.93M | 27.02M | 98.36M |
| NetTangibleAssets | 209.51M | 39.63M | -45.09M | 32.50M |
| CapitalLeaseObligations | 25.40M | 32.12M | 37.61M | 29.92M |
| CommonStockEquity | 209.51M | 39.63M | -45.09M | 32.50M |
| TotalCapitalization | 209.51M | 39.63M | -45.09M | 32.50M |
| TotalEquityGrossMinorityInterest | 209.51M | 39.63M | -45.09M | 32.50M |
| StockholdersEquity | 209.51M | 39.63M | -45.09M | 32.50M |
| GainsLossesNotAffectingRetainedEarnings | -262.00K | -124.00K | -29.00K | 181.00K |
| OtherEquityAdjustments | -262.00K | -124.00K | -29.00K | 181.00K |
| RetainedEarnings | -1.12B | -1.02B | -967.34M | -805.51M |
| AdditionalPaidInCapital | 156.45M | 129.24M | 119.44M | 87.98M |
| CapitalStock | 1.18B | 935.37M | 802.83M | 749.85M |
| CommonStock | 1.18B | 935.37M | 802.83M | 749.85M |
| TotalLiabilitiesNetMinorityInterest | 142.69M | 235.32M | 191.48M | 174.51M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 31.74M | 48.88M | 119.96M | 110.31M |
| OtherNonCurrentLiabilities | 190.00K | |||
| PreferredSecuritiesOutsideStockEquity | 7.87M | 7.87M | 7.87M | 7.87M |
| NonCurrentDeferredLiabilities | 6.10M | 15.60M | 79.77M | 77.48M |
| NonCurrentDeferredRevenue | 6.10M | 15.60M | 79.77M | 77.48M |
| LongTermDebtAndCapitalLeaseObligation | 17.77M | 25.40M | 32.12M | 24.95M |
| LongTermCapitalLeaseObligation | 17.77M | 25.40M | 32.12M | 24.95M |
| CurrentLiabilities | 110.95M | 186.44M | 71.52M | 64.20M |
| CurrentDeferredLiabilities | 65.97M | 150.06M | 31.56M | 37.10M |
| CurrentDeferredRevenue | 65.97M | 150.06M | 31.56M | 37.10M |
| CurrentDebtAndCapitalLeaseObligation | 7.64M | 6.71M | 5.50M | 4.96M |
| CurrentCapitalLeaseObligation | 7.64M | 6.71M | 5.50M | 4.96M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 15.36M | 14.06M | 12.29M | 10.18M |
| PayablesAndAccruedExpenses | 21.98M | 15.60M | 22.18M | 11.96M |
| CurrentAccruedExpenses | 5.72M | 2.76M | 5.26M | 4.68M |
| Payables | 16.26M | 12.84M | 16.91M | 7.28M |
| AccountsPayable | 16.26M | 12.84M | 16.91M | 7.28M |
| TotalAssets | 352.21M | 274.95M | 146.39M | 207.01M |
| TotalNonCurrentAssets | 31.81M | 39.58M | 47.85M | 44.44M |
| OtherNonCurrentAssets | 3.81M | 3.85M | 3.72M | 3.80M |
| NetPPE | 28.00M | 35.72M | 44.13M | 40.64M |
| AccumulatedDepreciation | -46.33M | -42.71M | -37.85M | -32.23M |
| GrossPPE | 74.33M | 78.43M | 81.97M | 72.87M |
| Leases | 28.89M | 28.52M | 28.41M | 27.99M |
| ConstructionInProgress | 349.00K | 294.00K | 318.00K | 28.00K |
| OtherProperties | 17.87M | 22.64M | 26.84M | 18.38M |
| MachineryFurnitureEquipment | 27.22M | 26.97M | 26.40M | 26.47M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 320.39M | 235.37M | 98.54M | 162.56M |
| OtherCurrentAssets | 7.35M | 4.02M | 2.11M | 5.42M |
| PrepaidAssets | 9.54M | 9.91M | 7.93M | 6.58M |
| Receivables | 1.42M | 21.09M | 0.00 | 0.00 |
| AccountsReceivable | 1.42M | 21.09M | 0.00 | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 302.08M | 200.35M | 88.50M | 150.56M |
| CashAndCashEquivalents | 302.08M | 200.35M | 88.50M | 150.56M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -151.96M | -20.55M | -129.14M | -89.55M |
| IssuanceOfCapitalStock | 236.18M | 131.28M | 52.33M | 54.97M |
| CapitalExpenditure | -938.00K | -1.11M | -1.36M | -560.00K |
| EndCashPosition | 305.84M | 204.05M | 92.16M | 154.22M |
| BeginningCashPosition | 204.05M | 92.16M | 154.22M | 188.15M |
| EffectOfExchangeRateChanges | -138.00K | -95.00K | -210.00K | -208.00K |
| ChangesInCash | 101.93M | 111.99M | -61.85M | -33.73M |
| FinancingCashFlow | 253.89M | 132.53M | 67.19M | 55.83M |
| CashFlowFromContinuingFinancingActivities | 253.89M | 132.53M | 67.19M | 55.83M |
| ProceedsFromStockOptionExercised | 17.71M | 1.26M | 14.86M | 858.00K |
| NetCommonStockIssuance | 236.18M | 131.28M | 52.33M | 54.97M |
| CommonStockIssuance | 236.18M | 131.28M | 52.33M | 54.97M |
| InvestingCashFlow | -938.00K | -1.11M | -1.25M | -560.00K |
| CashFlowFromContinuingInvestingActivities | -938.00K | -1.11M | -1.25M | -560.00K |
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 0.00 | 0.00 |
| SaleOfInvestment | 0.00 | 0.00 | 75.04M | 0.00 |
| PurchaseOfInvestment | 0.00 | 0.00 | -75.04M | 0.00 |
| NetPPEPurchaseAndSale | -938.00K | -1.11M | -1.25M | -560.00K |
| SaleOfPPE | 0.00 | 0.00 | 106.00K | 0.00 |
| PurchaseOfPPE | -938.00K | -1.11M | -1.36M | -560.00K |
| OperatingCashFlow | -151.03M | -19.43M | -127.78M | -88.99M |
| CashFlowFromContinuingOperatingActivities | -151.03M | -19.43M | -127.78M | -88.99M |
| ChangeInWorkingCapital | -75.82M | 19.08M | 6.72M | 7.01M |
| ChangeInOtherWorkingCapital | -93.59M | 54.33M | -3.25M | -18.46M |
| ChangeInOtherCurrentLiabilities | -6.71M | -5.69M | -4.12M | -4.36M |
| ChangeInOtherCurrentAssets | -3.23M | -2.01M | 3.39M | -338.00K |
| ChangeInPayablesAndAccruedExpense | 7.67M | -4.49M | 12.04M | -3.68M |
| ChangeInAccruedExpense | 4.25M | -724.00K | 2.69M | 2.89M |
| ChangeInPayable | 3.42M | -3.76M | 9.35M | -6.57M |
| ChangeInAccountPayable | 3.42M | -3.76M | 9.35M | -6.57M |
| ChangeInPrepaidAssets | 368.00K | -1.98M | -1.35M | 3.85M |
| ChangeInReceivables | 19.66M | -21.09M | 0.00 | 30.00M |
| ChangesInAccountReceivables | 19.66M | -21.09M | 0.00 | 30.00M |
| StockBasedCompensation | 13.14M | 9.79M | 17.19M | 16.41M |
| DepreciationAmortizationDepletion | 8.66M | 9.21M | 10.11M | 9.84M |
| DepreciationAndAmortization | 8.66M | 9.21M | 10.11M | 9.84M |
| Depreciation | 8.66M | 9.21M | 10.11M | 9.84M |
| OperatingGainsLosses | 12.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 0.00 | 12.00K | 0.00 |
| NetIncomeFromContinuingOperations | -97.01M | -57.51M | -161.82M | -122.25M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for WVE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|